EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

Postnatal and long-term outcomes after in utero exposure to RAAS inhibitors: cohort study based on German claims data

Tania Schink, Malte Braitmaier, Katarina Dathe, Ulrike Haug, Christof Schaefer, Kathrin Thöne, Marlies Onken

Pediatric Nephrology · 2026

DOI: 10.1007/s00467-025-07101-9 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Pediatric Nephrology, 2026. Verfasst von Tania Schink und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany. schink@leibniz-bips.de. Hauptthemen laut MEDLINE: Renin-Angiotensin System, Prenatal Exposure Delayed Effects, Angiotensin Receptor Antagonists, Antihypertensive Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovation Fund of the German Joint Federal Committee, Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS GmbH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Although use of inhibitors of the renin–angiotensin–aldosterone system (RAAS-I) is contraindicated in the second and third trimesters of pregnancy, a relevant number of pregnancies is still exposed. Fetopathy in children exposed after gestational week (GW) 20 is well described, but data on long-term outcomes are scarce. Our study aims to describe postnatal and long-term outcomes after fetal exposure to RAAS-I.

Methods

We included all pregnancies in the German Pharmacoepidemiological Research Database GePaRD (claims data; 20% of the total German population) with exposure to RAAS-I or the antihypertensives recommended during pregnancy, i.e., metoprolol or methyldopa (HYP) after GW 20. We assessed diagnoses characteristic of RAAS-I-related fetopathy in the first 180 days after birth and examined long-term outcomes of children with and without neonatal fetopathy, especially hypertension and kidney disease.

Results

Overall, we identified 203 live born children exposed to RAAS-I, of whom 61 were exposed to angiotensin II receptor blockers (ARBs), and 29,674 live born children exposed to HYP. Diagnoses consistent with RAAS-I-related fetopathy were seen in eight of the RAAS-I exposed newborns (3.9%) and in seven of the 61 ARB-exposed newborns (11.5%). Median follow-up in children without fetopathy was 4.0 years in both exposure groups. Among non-fetopathy children exposed to RAAS-I, three (1.5%) were diagnosed with hypertension or received antihypertensive prescriptions, compared to 176 children (0.6%) exposed to HYP.

Conclusions

Risk of fetopathy is higher after fetal exposure to ARBs than to angiotensin-converting enzyme inhibitors. In a small proportion of children, sequelae of fetal RAAS-I exposure might only manifest in the years following birth. Graphical Abstract

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Renin-Angiotensin SystemPrenatal Exposure Delayed EffectsAngiotensin Receptor AntagonistsAntihypertensive AgentsAngiotensin-Converting Enzyme InhibitorsHumansPregnancyFemaleGermanyInfant, NewbornMaleMethyldopaMetoprololHypertensionInfantCohort StudiesChildChild, PreschoolDatabases, FactualAdult

Stichwörter der Autor:innen

Angiotensin II type 1 receptor blockers (ARBs)Angiotensin-converting enzyme (ACE) inhibitorsDrug-related side effects and adverse reactionsLong-term outcomePregnancyRenin–angiotensin–aldosterone system inhibitors

Substanzen

Angiotensin Receptor AntagonistsAntihypertensive AgentsMethyldopaAngiotensin-Converting Enzyme InhibitorsMetoprolol

Autor:innen und Institutionen

  • Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany. schink@leibniz-bips.de.
  • Department of Statistical Methods in Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
  • Pharmakovigilanz- und Beratungszentrum für Embryonaltoxikologie, Institut für Klinische Pharmakologie und Toxikologie, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Univers…
  • Department of Clinical Epidemiology, Leibniz Institute for Prevention Research and Epidemiology - BIPS, Bremen, Germany.
  • Faculty of Human and Health Sciences, University of Bremen, Bremen, Germany.
  • Techniker Krankenkasse, Hamburg, Germany.

Förderung

  • Innovation Fund of the German Joint Federal Committee
  • Leibniz-Institut für Präventionsforschung und Epidemiologie – BIPS GmbH

Zitieren

APA

Schink, T., Braitmaier, M., Dathe, K., Haug, U., Schaefer, C., Thöne, K., & Onken, M. (2026). Postnatal and long-term outcomes after in utero exposure to RAAS inhibitors: cohort study based on German claims data. Pediatric Nephrology. https://doi.org/10.1007/s00467-025-07101-9

Vancouver

Schink T, Braitmaier M, Dathe K, Haug U, Schaefer C, Thöne K, et al. Postnatal and long-term outcomes after in utero exposure to RAAS inhibitors: cohort study based on German claims data. Pediatric Nephrology. 2026. doi:10.1007/s00467-025-07101-9

BibTeX
@article{Schink2026,
  author = {Schink, Tania and Braitmaier, Malte and Dathe, Katarina and Haug, Ulrike and Schaefer, Christof and Thöne, Kathrin and Onken, Marlies},
  title = {Postnatal and long-term outcomes after in utero exposure to RAAS inhibitors: cohort study based on German claims data},
  journal = {Pediatric Nephrology},
  year = {2026},
  doi = {10.1007/s00467-025-07101-9}
}
Kostenlos starten →